Arrowhead Research Corporation

Robbins LLP Is Investigating the Officers and Directors of Arrowhead Research Corporation (ARWR) on Behalf of Shareholders

Robbins LLP is investigating whether certain officers and directors of Arrowhead Research Corporation (NASDAQGS: ARWR) breached their fiduciary duties to shareholders. Arrowhead is a biopharmaceutical company that develops targeted RNAi therapeutics in the United States.

Arrowhead to Cut Hepatitis B Drug Study Dosage in Mid-Stage Trial

On January 12, 2015, Arrowhead stock fell over 23% to close at $6.90 per share after the company announced that the U.S. Food and Drug Administration verbally informed the company of a partial clinical hold on its ARC-520 study for patients with chronic hepatitis B. The FDA has informed Arrowhead that it will need to start a new, multi-dose study at one mg/kg instead of the proposed two and four mg/kg. In addition, the FDA has requested additional information from the drug’s current mid-stage study.

Arrowhead Shareholders Have Legal Options

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, or you can complete the form below and we will contact you directly.

Send us a message for more information.